My latest post at my other group blog, History and Futility, was entitled "Why Eurabia?" Why, in the face of the abundant evidence that the prospect of a Muslim majority in any European country--indeed, of particularly large Muslim minorities anywhere--do large numbers of people (like Glenn Beck) predict an imminent caliphate in Europe?Eurabia's fundamentally an ideology of revenge ("Ha, ha, you

Months after the gray market in China starting selling both iPad clones and the real devices, Apple officially began selling its tablet computer in China via its own retail shops and those of its partners last Friday, September 17. The Wi-Fi version iPad is available in Apple's specialty stores and its authorized retailers on the [...]

"There is a real possibility of not agreeing a 2011 budget," said the official, who has conducted extensive behind-the-scenes talks with members of the EU legislature, according to the EUobserver. The Belgian official said he feared euro deputies would use the 2011 budget discussions to show that parliament meant business ahead of the fast-approaching debate on the EU's next long-term spending programme (2014-2020)

Genzyme Corp. (GENZ) recently announced that the US Food and Drug Administration (FDA) has assigned an action date for the company’s Biologics License Application for Lumizyme (alglucosidase alfa) for the treatment of Pompe disease. Genzyme is seeking approval for Lumizyme which has been produced at its 4000 liter-scale manufacturing plant in Geel, Belgium. Earlier, Genzyme had submitted an application seeking approval for Lumizyme manufactured at its 2000 liter bioreactor scale at its Allston Landing manufacturing facility. However, the FDA issued a complete response letter in November 2009 stating it will not grant approval unless the company addresses the manufacturing issues at its Allston plant. Based on subsequent discussions with the agency, Genzyme announced that it would resubmit its application and seek approval for the manufacture of the product at the Geel plant. The FDA has classified the resubmission as a class 2 complete response and assigned a Prescription Drug User Fee Act ...